Chromatographia

, Volume 65, Issue 5–6, pp 355–358 | Cite as

Determination of Atazanavir in the Presence of its Degradation Products by a Stability-Indicating LC Method

  • U. Seshachalam
  • D. V. L. Narasimha Rao
  • B. Haribabu
  • K. B. Chandrasekhar
Full Short Communication

Abstract

A forced degradation study was successfully applied for the development of a stability-indicating assay method for the determination of atazanavir in presence of its degradation products. The method was developed and optimized by analyzing the forcefully degraded samples. Degradation of the drug was done under acidic, alkaline, oxidative, photolytic and thermal stress conditions. The proposed method was able to resolve all of the possible degradation products formed during the stress studies. The major impurities are generated in acidic and alkaline conditions. The product was found stable under thermal, photolytic and oxidative conditions. The developed method was validated for determination of atazanavir, and the method was found to be equality applicable to study the impurities formed during routine and forced degradation of atazanavir.

Keywords

Column liquid chromatography Stability-indicating method Forced degradation Drug substance Atazanavir 

References

  1. 1.
    ICH, International Conference on Harmonization of Technical Requirements for the Registration of Drugs for Human use (2003) Stability testing of new drug substances and products Q1A(R2)Google Scholar
  2. 2.
    ICH, International Conference on Harmonization of Technical Requirements for the Registration of Drugs for Human use (1996) Stability testing: photo stability testing of new drug substances and products Q1BGoogle Scholar
  3. 3.
    Mohammed J, Rao S, Gatz M, Whigan D (2003) J Chromatogr B 795:273–289CrossRefGoogle Scholar
  4. 4.
    Colombo S, Guignard N, Marzolini C, Telenti A, Biollaz J, Decosterd LA (2004) J Chromatogr B 810:25–34CrossRefGoogle Scholar
  5. 5.
    Cateau E, Tournier N, Dupuis A, Moal GL, Venisse N (2005) J Pharma Biomed Anal 39:791–795CrossRefGoogle Scholar
  6. 6.
    Dickinson L, Robinson L, Tjia J, Khoo S, Back D (2005) J Chromatogr B 829:82–90CrossRefGoogle Scholar
  7. 7.
    Poirier JM, Robidou P, Jaillon P (2005) Ther Drug Monit 27:186–192CrossRefGoogle Scholar
  8. 8.
    Sparidans RW, Dost F, Crommentuyn KML, Huitema ADR, Schellens JHM, Beijnen JH (2006) Biomed Chromatogr 20:72–76CrossRefGoogle Scholar
  9. 9.
    Notari S, Bocedi A, Ippolito G, Narciso P, Pucillo LP, Tossini G, Donnorso RP, Gasparrini F, Ascenzi P (2006) J Chromatogr B 831:258–266CrossRefGoogle Scholar
  10. 10.
    Xu RN, Fan L, Kim GE, Tawakol AE. (2006) J Pharma Biomed Anal 40:728–736CrossRefGoogle Scholar
  11. 11.
    Koal T, Sibum M, Koster E, Resch K, Kaever V (2006) Clin Chem Lab Med 44:299–305CrossRefGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlag/GWV Fachverlage GmbH 2006

Authors and Affiliations

  • U. Seshachalam
    • 1
  • D. V. L. Narasimha Rao
    • 2
  • B. Haribabu
    • 3
  • K. B. Chandrasekhar
    • 4
  1. 1.Quality AssuranceMatrix Laboratories LimitedSecunderabadIndia
  2. 2.Process Reseacrh LaboratoryMatrix Laboratories LimitedSecunderabadIndia
  3. 3.API Technical servicesMatrix Laboratories LimitedSecunderabadIndia
  4. 4.Department of ChemistryJNTU College of EngineeringAnanthapurIndia

Personalised recommendations